Dyne Therapeutics (NASDAQ:DYN) Director Buys $40,000.00 in Stock

Dyne Therapeutics, Inc. (NASDAQ:DYN) Director Brian Posner purchased 2,500 shares of the stock in a transaction that occurred on Friday, October 2nd. The shares were purchased at an average price of $16.00 per share, for a total transaction of $40,000.00. Following the completion of the purchase, the director directly owned 27,000 shares of the company’s stock, valued at approximately $432,000. This trade represents a 10.20% increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this link.

Dyne Therapeutics Stock Performance

Shares of DYN stock traded down $0.04 during mid-day trading on Tuesday, reaching $15.40. The stock had a trading volume of 4,091,193 shares, compared to its average volume of 2,276,174. Dyne Therapeutics, Inc. has a one year low of $12.77 and a one year high of $27.31. The firm has a market cap of $2.88 billion, a PE ratio of -4.62 and a beta of 1.12. The firm’s 50 day simple moving average is $22.31 and its 200 day simple moving average is $20.54. The company has a quick ratio of 12.02, a current ratio of 12.02 and a debt-to-equity ratio of 0.28.

Dyne Therapeutics (NASDAQ:DYN) last released its quarterly earnings data on Wednesday, July 29th. The company reported ($1.08) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.75) by ($0.33). On average, analysts forecast that Dyne Therapeutics, Inc. will post -3.59 EPS for the current year.

Hedge Funds Weigh In On Dyne Therapeutics

Institutional investors have recently bought and sold shares of the business. BlackRock Inc. bought a new stake in shares of Dyne Therapeutics during the second quarter worth $275,500,000. Jupiter Topco LLC acquired a new stake in Dyne Therapeutics in the 2nd quarter valued at about $266,634,000. Perceptive Advisors LLC increased its position in Dyne Therapeutics by 34.2% in the 1st quarter. Perceptive Advisors LLC now owns 4,668,839 shares of the company’s stock valued at $84,646,000 after acquiring an additional 1,189,895 shares in the last quarter. Armistice Capital LLC raised its stake in shares of Dyne Therapeutics by 6.1% in the fourth quarter. Armistice Capital LLC now owns 3,249,708 shares of the company’s stock worth $63,564,000 after acquiring an additional 185,708 shares during the last quarter. Finally, Frazier Life Sciences Management L.P. raised its stake in shares of Dyne Therapeutics by 16.0% in the fourth quarter. Frazier Life Sciences Management L.P. now owns 3,153,082 shares of the company’s stock worth $61,674,000 after acquiring an additional 434,977 shares during the last quarter. Institutional investors own 96.68% of the company’s stock.

Analysts Set New Price Targets

Several brokerages have recently weighed in on DYN. HC Wainwright decreased their target price on shares of Dyne Therapeutics from $50.00 to $32.00 and set a “buy” rating on the stock in a research report on Wednesday, September 30th. Jefferies Financial Group reaffirmed a “buy” rating and set a $50.00 price objective on shares of Dyne Therapeutics in a report on Wednesday, September 30th. Morgan Stanley lowered their price objective on Dyne Therapeutics from $45.00 to $36.00 and set an “overweight” rating on the stock in a research note on Wednesday, September 9th. Piper Sandler restated an “overweight” rating and set a $47.00 target price on shares of Dyne Therapeutics in a research report on Tuesday, September 29th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Dyne Therapeutics in a research note on Friday, July 17th. Two research analysts have rated the stock with a Strong Buy rating, twelve have issued a Buy rating, one has issued a Hold rating and two have issued a Sell rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $33.07.

About Dyne Therapeutics

Dyne Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on developing genetic medicines for serious neuromuscular diseases. The company’s research is centered on its FORCE platform, which is designed to use targeted antibodies to deliver oligonucleotide-based therapies to skeletal muscle and other relevant tissues.

Dyne’s development programs include DYNE-101, an investigational therapy for myotonic dystrophy type 1, and DYNE-251, an investigational exon-skipping therapy for Duchenne muscular dystrophy in patients amenable to exon 51 skipping.